Denali Therapeutics/$DNLI

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Denali Therapeutics

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Ticker

$DNLI
Primary listing

Industry

Biotechnology

Employees

443

ISIN

US24823R1059

DNLI Metrics

BasicAdvanced
$2.1B
-
-$2.67
1.33
-

What the Analysts think about DNLI

Analyst ratings (Buy, Hold, Sell) for Denali Therapeutics stock.

Bulls say / Bears say

Denali Therapeutics' lead candidate, tividenofusp alfa (DNL310), received FDA Breakthrough Therapy Designation for Hunter syndrome, indicating strong potential for accelerated approval and market entry. (globenewswire.com)
Analysts have shown confidence in Denali's prospects, with Baird initiating coverage with an 'Outperform' rating and a $31 price target, suggesting significant upside potential. (nasdaq.com)
Denali maintains a robust cash position of $1.2 billion as of December 2024, providing financial stability to advance its pipeline and commercial initiatives. (panabee.com)
Denali reported a net loss of $423 million in 2024, a significant increase from the $145 million loss in 2023, raising concerns about financial sustainability. (panabee.com)
The company halted its Phase 2 multiple sclerosis study of oditrasertib (SAR443820/DNL788) due to failure to meet primary and key secondary endpoints, indicating potential challenges in its clinical pipeline. (investing.com)
Denali underwent a reorganization, including layoffs and spinning off its preclinical small molecule portfolio, which may signal internal challenges and strategic shifts. (fiercebiotech.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.

DNLI Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

DNLI Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DNLI

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs